ArticleJMIR research protocols2026
The Digital Diabetes Patient Reminder Tool for Adults With Type 2 Diabetes: Protocol for a Proof-of-Concept Randomized Controlled Trial.
Article in JMIR research protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: About 828 million adults were estimated to be living with diabetes, and this is projected to affect 1 in 9 adults by 2045. In Belgium, 7.6% of adults have been diagnosed with the disease; however, approximately 1 in 3 people remain unaware of their condition. Advances in information and communication technology (ICT) have improved care quality and health management, and facilitated communication between health care providers and patients. The Digital Diabetes Patient Reminder (DIPAR) tool was developed as an extension of the existing patient portal to support diabetes management through automated reminders for overdue monitoring, and a consultation dashboard that facilitates communication between patients and health care providers. This pilot study was conducted within the European Joint Action on Cardiovascular Diseases and Diabetes framework. Objective: This trial aims to evaluate whether the implementation of the DIPAR tool improves adherence to recommended diabetes follow-up. The primary objective is to determine whether the intervention increases the proportion of adults with type 2 diabetes mellitus (T2DM) who receive at least one documented annual albuminuria measurement in the electronic medical records (EMR). The key secondary objective is to assess whether the intervention increases the proportion of patients with at least 2 documented hemoglobin A Methods: This multicenter, pragmatic, parallel-group, proof-of-concept randomized controlled trial (RCT) will recruit approximately 200 adults with T2DM receiving outpatient diabetes care at 2 hospitals in Flanders, Belgium. Participants will be randomized (1:1), stratified only by study center, to receive either the DIPAR tool extension in addition to usual care or usual care alone using the standard patient portal. The intervention consists of automated reminders for timely follow-up and a consultation dashboard to be used by patients and physicians. The intervention will last 12 months. Clinical outcomes will be extracted from the EMR, while usability and acceptability will be evaluated using the Dutch and English versions of the Mobile Health App Usability Questionnaire (MAUQ), semistructured interviews, and focus group discussions. The primary analysis will follow the intention-to-treat principle using regression-based methods appropriate for each outcome. Results: Recruitment started in October 2025 and was completed in December 2025. A total of 201 patients were recruited, with 100 participants allocated to the intervention group. Data extraction did not commence until March 2026, after the completion of the statistical analysis plan and the protocol submission. Data analysis has not started. Conclusions: This study will provide insights into the potential added value of a digital reminder tool for T2DM management in a real-world setting as well as the usability and acceptability of this tool.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.